Aurinia Pharmaceuticals - AUPH Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Moderate Buy
Consensus Price Target: $10.00
Forecasted Upside: 98.81%
Number of Analysts: 4
Breakdown:
0 Sell Ratings
1 Hold Ratings
3 Buy Ratings
0 Strong Buy Ratings

^$5.03 As of 04/24/2024 06:22 PM ET

▼ -0.06 (-1.18%)

1 month | 3 months | 12 months

Get New Aurinia Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for AUPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AUPH

^$10.00

▲ +98.81% Upside Potential

This price target is based on 4 analysts offering 12 month price targets for Aurinia Pharmaceuticals in the last 3 months. The average price target is $10.00, with a high forecast of $13.00 and a low forecast of $8.00. The average price target represents a 98.81% upside from the last price of $5.03.

Current Consensus is Moderate Buy

The current consensus among 4 polled investment analysts is to moderate buy stock in Aurinia Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

10/31/2022

0 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

1/29/2023

0 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

4/29/2023

0 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

7/28/2023

0 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

10/26/2023

0 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

1/24/2024

0 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

3/24/2024

0 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

4/23/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/1/2024	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$13.00	Low
2/23/2024	Cantor Fitzgerald	Lower Target	Overweight ➝ Overweight	$12.00 ➝ $10.00	Low
2/22/2024	HC Wainwright	Lower Target	Buy ➝ Buy	$15.00 ➝ $13.00	Low
2/16/2024	Jefferies Financial Group	Lower Target	Hold	$9.50 ➝ $9.00	Low
2/16/2024	Royal Bank of Canada	Lower Target	Outperform ➝ Outperform	$13.00 ➝ $8.00	Low
9/22/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$15.00	Low
8/7/2023	HC Wainwright	Boost Target	Buy ➝ Buy	$14.00 ➝ $15.00	Low
5/2/2023	Royal Bank of Canada	Boost Target	Outperform	$11.00 ➝ $13.00	Low
2/23/2023	Royal Bank of Canada	Reiterated Rating	Outperform	$11.00	Low
1/3/2023	Royal Bank of Canada	Boost Target	Outperform	$10.00 ➝ $11.00	Low
11/7/2022	HC Wainwright	Lower Target	Buy	$26.00 ➝ $14.00	Low
11/4/2022	Royal Bank of Canada	Lower Target	Outperform	$18.00 ➝ $10.00	Low
11/4/2022	SVB Leerink	Lower Target	Outperform	$17.00 ➝ $12.00	Low
11/4/2022	Oppenheimer	Downgrade	Outperform ➝ Market Perform		Low
8/9/2022	HC Wainwright	Lower Target	Buy	$30.00 ➝ $26.00	Low
8/8/2022	Oppenheimer	Lower Target	Outperform	$15.00 ➝ $13.00	Low
8/5/2022	Royal Bank of Canada	Lower Target	Outperform	$22.00 ➝ $18.00	Low
5/4/2022	HC Wainwright	Lower Target		$33.00 ➝ $30.00	High
4/28/2022	Cantor Fitzgerald	Reiterated Rating	Overweight		High
4/28/2022	Royal Bank of Canada	Lower Target	Outperform	$27.00 ➝ $22.00	High
4/1/2022	Cantor Fitzgerald	Reiterated Rating	Overweight		N/A
3/8/2022	SVB Leerink	Lower Target	Outperform	$30.00 ➝ $22.00	High
3/1/2022	HC Wainwright	Reiterated Rating	Buy	$40.00 ➝ $33.00	Low
3/1/2022	Royal Bank of Canada	Lower Target	Outperform	$31.00 ➝ $27.00	Medium
2/23/2022	Royal Bank of Canada	Lower Target	Outperform	$34.00 ➝ $31.00	High
12/15/2021	Jefferies Financial Group	Reiterated Rating	Buy		High
12/10/2021	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$33.00 ➝ $31.00	High
11/4/2021	Oppenheimer	Boost Target	Market Perform	$32.00 ➝ $33.00	Low
11/4/2021	HC Wainwright	Boost Target	Buy	$35.00 ➝ $40.00	Medium
11/4/2021	SVB Leerink	Boost Target	Outperform	$28.00 ➝ $35.00	Medium
10/28/2021	Oppenheimer	Downgrade	Outperform ➝ Market Perform	$28.00 ➝ $32.00	Medium
10/26/2021	Royal Bank of Canada	Boost Target	Outperform	$23.00 ➝ $34.00	High
10/1/2021	Bloom Burton	Initiated Coverage	Hold	$23.00	Medium
8/19/2021	SVB Leerink	Reiterated Rating	Buy		Low
5/7/2021	Bloom Burton	Upgrade	Accumulate ➝ Buy		High
5/7/2021	Royal Bank of Canada	Lower Target	Outperform	$26.00 ➝ $23.00	Medium
5/7/2021	Oppenheimer	Reiterated Rating	Buy		High
4/11/2021	SVB Leerink	Reiterated Rating	Buy		Medium
2/25/2021	Royal Bank of Canada	Lower Target	Outperform	$28.00 ➝ $26.00	Low
1/27/2021	SVB Leerink	Boost Target	Outperform	$24.00 ➝ $28.00	High
1/26/2021	Royal Bank of Canada	Boost Target	Average ➝ Outperform	$20.00 ➝ $28.00	High
1/26/2021	Cantor Fitzgerald	Boost Target	Overweight	$27.00 ➝ $34.00	High
1/25/2021	Oppenheimer	Boost Target		$20.00 ➝ $28.00	High
1/25/2021	HC Wainwright	Boost Target	Buy	$30.00 ➝ $35.00	High
12/18/2020	HC Wainwright	Boost Target	Buy	$28.00 ➝ $30.00	Medium
12/17/2020	Oppenheimer	Reiterated Rating	Buy	$20.00	Medium
11/12/2020	Cantor Fitzgerald	Lower Target		$30.00 ➝ $26.00	Low
11/3/2020	Bloom Burton	Downgrade	Buy ➝ Accumulate		Low
11/3/2020	HC Wainwright	Lower Target	Buy	$34.00 ➝ $28.00	Medium
8/13/2020	Royal Bank of Canada	Reiterated Rating	Buy		Low
8/12/2020	HC Wainwright	Boost Target	Buy	$33.00 ➝ $34.00	Low
7/22/2020	HC Wainwright	Boost Target	Buy	$32.00 ➝ $33.00	Medium
6/16/2020	BTIG Research	Initiated Coverage	Buy	$20.00	Low
5/17/2020	Royal Bank of Canada	Reiterated Rating	Buy	$20.00	Low
5/14/2020	Oppenheimer	Initiated Coverage	Buy	$22.00	Low
5/5/2020	Cowen	Initiated Coverage	Outperform		High
4/20/2020	HC Wainwright	Reiterated Rating	Buy	$32.00	High
3/19/2020	Bloom Burton	Reiterated Rating	Buy	$23.00	Low
3/9/2020	Royal Bank of Canada	Reiterated Rating	Buy		Medium
3/6/2020	Cantor Fitzgerald	Boost Target	Overweight	$30.00 ➝ $32.00	High
1/10/2020	Jefferies Financial Group	Initiated Coverage	Buy	$27.00	Medium
12/16/2019	HC Wainwright	Boost Target	Buy	$25.00 ➝ $32.00	Low
12/5/2019	Cantor Fitzgerald	Boost Target		$24.00 ➝ $30.00	Low
12/5/2019	Oppenheimer	Boost Target		$14.00 ➝ $22.00	Low
12/5/2019	Royal Bank of Canada	Boost Target	Outperform	$11.00 ➝ $20.00	N/A
11/1/2019	HC Wainwright	Set Target	Buy	$25.00	Low
10/17/2019	Cantor Fitzgerald	Reiterated Rating	Overweight		Low
10/2/2019	Bloom Burton	Reiterated Rating	Buy		Low
9/10/2019	Oppenheimer	Initiated Coverage	Outperform	$14.00 ➝ $14.00	High
9/9/2019	Citigroup	Initiated Coverage	Outperform	$14.00	High
8/8/2019	Royal Bank of Canada	Reiterated Rating	Buy	$11.00	Medium
6/4/2019	HC Wainwright	Reiterated Rating	Buy	$25.00	Low
5/23/2019	HC Wainwright	Reiterated Rating	Buy	$15.00 ➝ $25.00	Medium
5/15/2019	HC Wainwright	Reiterated Rating	Buy		High

(Data available from 4/24/2019 forward)

News Sentiment Rating

0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

5 very positive mentions
4 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

9/27/2023

3 very positive mentions
4 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

10/27/2023

4 very positive mentions
5 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

11/26/2023

2 very positive mentions
4 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

12/26/2023

3 very positive mentions
0 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

1/25/2024

3 very positive mentions
13 positive mentions
5 negative mentions
1 very negative mentions

Mentions as of

2/24/2024

6 very positive mentions
7 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

3/25/2024

3 very positive mentions
6 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

4/24/2024

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Today's Range

Now: $5.03

$5.00

$5.16

50 Day Range

MA: $5.37

$4.81

$7.97

52 Week Range

Now: $5.03

$4.71

$12.43

Volume

785,988 shs

Average Volume

2,161,886 shs

Market Capitalization

$727.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.36

Frequently Asked Questions

What sell-side analysts currently cover shares of Aurinia Pharmaceuticals?: The following Wall Street sell-side analysts have issued research reports on Aurinia Pharmaceuticals in the last twelve months: Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group Inc., Royal Bank of Canada, and StockNews.com.
View the latest analyst ratings for AUPH.
What is the current price target for Aurinia Pharmaceuticals?: 4 Wall Street analysts have set twelve-month price targets for Aurinia Pharmaceuticals in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 98.8%. HC Wainwright has the highest price target set, predicting AUPH will reach $13.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $8.00 for Aurinia Pharmaceuticals in the next year.
View the latest price targets for AUPH.
What is the current consensus analyst rating for Aurinia Pharmaceuticals?: Aurinia Pharmaceuticals currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for AUPH.
What other companies compete with Aurinia Pharmaceuticals?: Other companies that are similar to Aurinia Pharmaceuticals include Longboard Pharmaceuticals, Ocular Therapeutix, Arcturus Therapeutics, Pliant Therapeutics and PureTech Health. Learn More about companies similar to Aurinia Pharmaceuticals.
How do I contact Aurinia Pharmaceuticals' investor relations team?: Aurinia Pharmaceuticals' physical mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The biotechnology company's listed phone number is 250-708-4272 and its investor relations email address is [email protected]. The official website for Aurinia Pharmaceuticals is www.auriniapharma.com. Learn More about contacing Aurinia Pharmaceuticals investor relations.

Aurinia Pharmaceuticals - AUPH Stock Price Target and Predictions

Analyst Price Target for AUPH

Current Consensus is Moderate Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.35 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Aurinia Pharmaceuticals?

What is the current price target for Aurinia Pharmaceuticals?

What is the current consensus analyst rating for Aurinia Pharmaceuticals?

What other companies compete with Aurinia Pharmaceuticals?

How do I contact Aurinia Pharmaceuticals' investor relations team?